A preliminary assessment of side effects from commonly used drugs for diabetes and obesity has not shown a link with suicidal thoughts or actions, according to the U.S. Food and Drug Administration (FDA).
The FDA emphasized that while there is no definitive evidence of such a link, a small risk cannot be entirely ruled out. The agency will continue to investigate reports concerning over a dozen drugs, including Ozempic, Wegovy, and Mounjaro. Patients taking these drugs are encouraged to report any concerns to their healthcare providers.
The review was prompted by anecdotal reports of suicidal thoughts among individuals taking semaglutide, the medication in Ozempic and Wegovy. A recent federally funded study indicated a lower risk of suicidal thoughts with semaglutide compared to other drugs for obesity and diabetes.
The FDA is analyzing reports on GLP-1 receptor agonists, medications approved since 2005 to control blood sugar levels and reduce the risk of heart disease in type 2 diabetes patients, some of which are also used for weight management.
